Human skin permeation of branched-chain 3-O-alkyl ester and carbonate prodrugs of naltrexone

Pharmaceutical Research

Volumn 22, Issue 5, 2005, Pages 758-765

  Vaddi, Haranath K ^a,b   Hamad, Mohamed O ^a   Chen, Jianhong ^a   Banks, Stan L ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Bioconversion; Branched chains; Naltrexone; Prodrugs; Skin permeation

Indexed keywords

NALTREXONE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; MELTING POINT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SKIN PERMEABILITY; STRATUM CORNEUM; THERMAL ANALYSIS; THERMODYNAMICS;

ABDOMEN; CARBONATES; DRUG DELIVERY SYSTEMS; ESTERS; HALF-LIFE; HUMANS; MINERAL OIL; NALTREXONE; PRODRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SKIN; SKIN ABSORPTION; SOLUBILITY; TRANSITION TEMPERATURE;

EID: 20044383036     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-005-2592-9     Document Type: Article

References (21)

1. A. Vigroux, M. Bergon, and C. Zedde. Cyclization-activated prodrugs: N-(substituted 2-hydroxyphenyl and 2-hydroxypropyl)carbamates based on ring-opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. J. Med. Chem. 38:3983-3994 (1995).
2. P. Vlieghe, F. Bihel, T. Clerc, C. Pannecouque, M. Witvrouw, E. D. Clercq, J. P. Salles, J. C. Chermann, and J. L. Kraus. New 3′-azido- 3′-deoxythymidin-5′-yl O-(ω-hydroxyalkyl) carbonate prodrugs: synthesis and anti-HIV evaluation. J. Med. Chem. 44: 777-786 (2001).
3. M. A. Hussain, C. A. Koval, M. J. Myers, E. G. Shami, and E. Shefter. Improvement of the oral bioavailability of naltrexone in dogs. J. Pharm. Sci. 76:356-358 (1987).
4. M. A. Hussain, B. J. Aungst, C. A. Koval, and E. Shefter. Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs. Pharm. Res. 5:615-618 (1988).
5. R. B. Greenwald, Y. H. Choe, C. D. Conover, K. Shum, D. Wu, and M. Royzen. Drug delivery systems based on trimethyl lock lactonization: poly(ethyleneglycol) prodrugs of amino-containing compounds. J. Med. Chem. 43:475-487 (2000).
6. J. R. Volpicelli, A. I. Alterman, and M. Hayashida. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49: 876-880 (1992).
7. L. Terenius. Rational treatment of addiction. Curr. Opin. Chem. Biol. 2:541-547 (1998).
8. J. L. Rothenberg, M. A. Sullivan, S. H. Church, A. Seracini, E. Collins, H. D. Kleber, and E. V. Nunes. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J. Subst. Abuse Treat. 23:351-360 (2002).
9. J. R. Volpicelli, K. C. Rhines, and J. S. Rhines. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry 54:737-743 (1997).
10. H. R. Kranzler, V. M. Lowe, and J. V Kirk. Naltrexone vs nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropyschopharmacol 22:493-503 (2000).
11. P. D. R. Generics. Medical Economics, 2nd ed., Medical Economics, Montvale, New Jersey, 1996, pp. 2229-2233.
12. Y. L. Chen, L. L Chun, and D. J. Enscore. Transdermal therapeutic systems for the administration of naloxone, naltrexone, and nalbuphine. Alza U.S. Patent No. 4 573 995. March 4, 1986.
13. A. L. Stinchcomb, P. W. Swaan, O. Ekabo, K. E. Harris, J. Browe, D. C. Hammell, T. A. Cooperman, and M. Pearsall. Straight-chain naltrexone ester prodrugs: diffusion and concurrent biotransformation in human skin. J. Pharm. Sci. 91:2571-2578 (2002).
14. O. Pillai, M. O. Hamad, P. A. Crooks, and A. L. Stinchcomb. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm. Res. 21:1146-1152 (2004).
15. A. M. Kilgman and E. Christophers. Preparation of isolated sheets of human stratum corneum. Arch. Dermatol. 88:702-705 (1963).
16. A. L. Stinchcomb, R. Dua, A. Paliwal, R. W. Woodard, and G. L. Flynn. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm. Res. 10: 1526-1529 (1995).
17. W. J. Roberts and K. B. Sloan. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine with a series/parallel model. J. Pharm. Sci. 89:1415-1431 (2000).
18. W. J. Roberts and K. B. Sloan. Correlation of aqueous and lipid solubilities with flux of prodrugs of 5-fluorouracil, theophylline and 6-mercaptopurine: A Potts-Guy approach. J. Pharm. Sci. 88: 515-522 (1999).
19. P. G. Hewitt, J. Perkins, and S. A. M. Hotchkiss. Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. I: during percutaneous absorption through fresh rat and human skin in vitro. Drug Metab. Dispos. 28:748-754 (2000).
20. E. Carvalho, A. P. Francisco, J. Iley, and E. Rosa. Triazene drug metabolites. Part 17: Synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour Triazenes. Bioorg. Med. Chem. 8:1719-1725 (2000).
21. M. Safadi, R. Oliyai, and V. J. Stella. Phophoryloxymethyl carbamates and carbonates-novel water soluble prodrugs for amines and hindered alcohols. Pharm. Res. 10:1350-1355 (1993).